EMEA Cancer Biological Therapy Market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Forecast to 2032

1 Report Prologue

2 INTRODUCTION

2.1 definition

2.2 Scope of Study:

2.2.1 Research Objective

2.3 MARKET STRUCTURE

3 Research Process:

3.1 Primary Research:

3.2 Secondary Research:

3.3 top-down & bottom-up approach:

4 MARKET DYNAMICS

4.1 DRIVERS

4.1.1 Increasing Cancer Survival Rate

4.1.2 Growing demand for advanced therapies

4.1.3 Less number of side effects as compared to conventional treatment methods

4.1.4 Growth of cancer healthcare facilities in emerging countries 16

4.1.5 chainging lifestyle and increasing smoking population in middle east & africa

4.2 RESTRAINTS

4.2.1 High cost of Cancer biological therapy

4.3 Opportunities

4.3.1 UnTapped types of Cancers

4.4 MACROECONOMIC INDICATORS

5 EMEA Cancer biological therapy, by phases

5.1 Introduction

5.2 Phases

6 EMEA Cancer Biological Therapy Market, BY Type

6.1 key findings

6.2 Monoclonal Antibodies

6.3 Interferons

6.4 Interleukins

6.5 Cancer growth inhibitors

6.6 Gene Therapy

6.7 Colony-Stimulating Factors

6.8 Targeted Therapy

6.9 CANCER VACCINES

7 EMEA Cancer Biological Therapy market, by end-users

7.1 key findings

7.2 Introduction

7.3 Hospitals & Clinics

7.4 Cancer Research Centers

7.5 Laboratories

8 EMEA Cancer Biological Therapy, by Region

8.1 key findings

EMEA Cancer biological therapy, by phases

EMEA Cancer Biological Therapy Market, BY Type

EMEA Cancer Biological Therapy market, by end-users

EMEA Cancer Biological Therapy Market, By Company

8.2 Europe 31

EMEA Cancer biological therapy, by phases

EMEA Cancer Biological Therapy Market, BY Type

EMEA Cancer Biological Therapy market, by end-users

EMEA Cancer Biological Therapy Market, By Company

8.3 Middle East & Africa

EMEA Cancer biological therapy, by phases

EMEA Cancer Biological Therapy Market, BY Type

EMEA Cancer Biological Therapy market, by end-users

EMEA Cancer Biological Therapy Market, By Company

9 Competitive landscape

9.1 Market Share Analysis

10 EMEA Cancer Biological Therapy Market, By Company

10.1 Amgen Inc.

10.1.1 Overview

10.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.1.3 FINANCIAL UPDATES

10.1.4 KEY DEVELOPMENTS

10.2 Bristol-Myers Squibb

10.2.1 Overview

10.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.2.3 FINANCIAL UPDATES

10.2.4 KEY DEVELOPMENTS

10.3 Celgene Corporation

10.3.1 Overview

10.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.3.3 FINANCIAL UPDATES

10.3.4 KEY DEVELOPMENTS

10.4 ELI Lilly and Company

10.4.1 Overview

10.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.4.3 FINANCIAL UPDATES

10.4.4 KEY DEVELOPMENTS

10.5 EnGeneIC Ltd

10.5.1 Overview

10.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.5.3 Financials UPDATES

10.5.4 Key Developments

10.6 F. Hoffmann-La Roche AG

10.6.1 Overview

10.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.6.3 FINANCIAL UPDATES

10.6.4 KEY DEVELOPMENTS

10.7 Merck & Co., Inc.

10.7.1 Overview

10.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.7.3 FINANCIAL UPDATES

10.7.4 KEY DEVELOPMENTS

10.8 Novartis

10.8.1 Overview

10.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.8.3 FINANCIAL UPDATES

10.8.4 KEY DEVELOPMENTS

10.9 pfizer Inc.

10.9.1 Overview

10.9.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.9.3 FINANCIAL UPDATES

10.9.4 KEY DEVELOPMENTS

10.10 Seattle Genetics, Inc.

10.10.1 Overview

10.10.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.10.3 FINANCIAL UPDATES

10.10.4 key developments

10.11 Teva Pharmaceutical Industries Ltd

10.11.1 Overview

10.11.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.11.3 Financials

10.11.4 Key Developments

11 List of Tables

TABLE 1 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION) 23

TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) 24

TABLE 3 INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 25

TABLE 4 INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 26

TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 27

TABLE 6 GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 28

TABLE 7 COLONY STIMULATING FACTOR FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 29

TABLE 8 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER, 2020-2027 (USD MILLION) 31

TABLE 9 HOSPITALS & CLINICS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 31

TABLE 10 CANCER RESEARCH CENTERS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 32

TABLE 11 LABORATORIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 33

TABLE 12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 35

TABLE 13 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 37

TABLE 14 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 38

TABLE 15 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 39

TABLE 16 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 40

TABLE 17 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 41

TABLE 18 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 42

TABLE 19 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 43

TABLE 20 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 45

TABLE 21 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 46

TABLE 22 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 47

TABLE 23 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 48

TABLE 24 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 49

TABLE 25 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 50

TABLE 26 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 51

TABLE 27 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 52

TABLE 28 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 53

TABLE 29 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 54

TABLE 30 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 55

TABLE 31 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 56

TABLE 32 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 57

TABLE 33 ROE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 58

TABLE 34 ROE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 59

TABLE 35 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 61

TABLE 36 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 62

TABLE 37 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 63

TABLE 38 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 64

TABLE 39 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 65

TABLE 40 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 66

TABLE 41 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 67

TABLE 42 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 68

TABLE 43 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 69

TABLE 44 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 70

TABLE 45 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 71

TABLE 46 ROA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 72

TABLE 47 ROA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 73

TABLE 48 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 74

TABLE 49 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 75

TABLE 50 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 76

TABLE 51 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 80

TABLE 52 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 81

TABLE 53 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 82

TABLE 54 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 83

TABLE 55 AMGEN INC.: KEY DEVELOPMENT 87

12 List of Figures

FIGURE 1 RESEARCH PROCESS 14

FIGURE 2 MARKET DYNAMICS FOR GLOBAL CANCER BIOLOGICAL THERAPY MARKET 16

FIGURE 3 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2020 (%) 20

FIGURE 4 CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS 21

FIGURE 5 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY TYPE 2020 22

FIGURE 6 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY END USER, 2020 30

FIGURE 7 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY REGION, 2020 34

FIGURE 8 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 37

FIGURE 9 EUROPE CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 45

FIGURE 10 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 61

FIGURE 11 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2020 73

FIGURE 12 QATAR: CANCER INCIDENCE AND MORTALITY RATES (%) 77

FIGURE 13 UAE: CANCER INCIDENCE AND MORTALITY RATES (%) 77

FIGURE 14 KUWAIT: CANCER INCIDENCE AND MORTALITY RATES (%) 78

FIGURE 15 BAHRAIN: CANCER INCIDENCE AND MORTALITY RATES (%) 78

FIGURE 16 OMAN: CANCER INCIDENCE AND MORTALITY RATES (%) 79

FIGURE 17 SAUDI ARABIA: CANCER INCIDENCE AND MORTALITY RATES (%) 79

FIGURE 18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 84

FIGURE 19 AMGEN INC.: KEY FINANCIALS 86

FIGURE 20 AMGEN INC.: SEGMENTAL REVENUE 86

FIGURE 21 AMGEN INC.: GEOGRAPHICAL REVENUE 87

FIGURE 22 BRISTOL-MYERS SQUIBB.: KEY FINANCIALS 89

FIGURE 23 BRISTOL-MYERS SQUIBB.: SEGMENTAL REVENUE 89

FIGURE 24 BRISTOL-MYERS SQUIBB: GEOGRAPHICAL REVENUE 90

FIGURE 25 CELGENE CORPORATION.: KEY FINANCIALS 92

FIGURE 26 CELGENE CORPORATION.: SEGMENTAL REVENUE 92

FIGURE 27 CELGENE CORPORATION: GEOGRAPHICAL REVENUE 93

FIGURE 28 ELI LILLY AND COMPANY.: KEY FINANCIALS 95

FIGURE 29 ELI LILLY AND COMPANY.: SEGMENTAL REVENUE 95

FIGURE 30 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE 96

FIGURE 31 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE 99

FIGURE 32 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE 99

FIGURE 33 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL REVENUE 100

FIGURE 34 MERCK & CO., INC: FINANCIAL REVENUE 102

FIGURE 35 MERCK & CO., INC: SEGMENTAL REVENUE 102

FIGURE 36 MERCK & CO., INC: GEOGRPAHICAL REVENUE 103

FIGURE 37 NOVARTIS: FINANCIAL REVENUE 105

FIGURE 38 NOVARTIS: SEGMENTAL REVENUE 105

FIGURE 39 NOVARTIS: GEOGRPAHICAL REVENUE 106

FIGURE 40 PFIZER INC: FINANCIAL REVENUE 108

FIGURE 41 PFIZER INC: SEGMENTAL REVENUE 108

FIGURE 42 PFIZER INC: GEOGRPAHICAL REVENUE 109